ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0943

Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positive SLE Patients on Estrogen-Containing Contraception

Hiba Bilal1, Amarah Baluch2 and Andras Perl3, 1SUNY Upstate Medical Unviersity, Jamesville, NY, 2SUNY Upstate Medical University, Syracuse, NY, 3SUNY, Syracuse, NY

Meeting: ACR Convergence 2022

Keywords: antiphospholipid syndrome, Systemic lupus erythematosus (SLE), Women's health

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Women of child-bearing age with underlying rheumatic disease such as systemic lupus erythematous (SLE) with positive anti-phospholipid antibodies (aPL) are at an increased risk of thrombosis. American College of Rheumatology (ACR) strongly recommends against the use of combined estrogen-progestin contraceptives in women with rheumatologic disease with positive aPL due to increased risk of thromboembolism. There is a strong recommendation for intrauterine devices (IUD) or the progestin-only pill in this population. The depo-medroxyprogesterone acetate intramuscular shot is not recommended due to limited data based on non-rheumatological disease patients suggesting that it results in higher thrombotic risk. The progestin implant is not recommended due to insufficient data. We investigated rates of thrombotic events in SLE patients with positive aPL on various forms of contraception.

Methods: Female patients age >18 years from January 2012- December 2021 with SLE and aPL testing were included in this study. These patients were divided into those with at least one positive aPL test and those with negative testing. The group with positive aPL testing was sub-categorized into those receiving contraception; this group was further sub-categorized into those receiving estrogen-based contraception (defined as oral combined estrogen-progestin pills) and those receiving progestin-based contraception (defined as levonorgestrel IUD, progestin only pill, depo-medroxyprogesterone acetate intramuscular shot or progestin implant). Lastly, the group receiving progestin-based contraception was divided into the specific form of progestin-contraception used and these groups were compared to one another. The primary end point in all groups was incidence of a thrombotic event defined as a cerebrovascular accident (CVA), pulmonary embolus (PE), or deep venous thrombosis (DVT). Statistical analysis was based on two-tailed chi-square test using GraphPad software. A p value < 0.05 was considered significant.

Results: SLE patients with positive aPL had a statistically significant increase in thrombotic events (Table 1) and those on estrogen-based contraception had a statistically significant increase in thrombotic events compared to those receiving progestin-based contraception (Table 2). Next, each form of progestin-based contraception was compared to one another and there was no statistically significant difference in thrombotic events between groups (Table 3).

Conclusion: Combined estrogen-progestin contraception in SLE patients with positive aPL conferred an increased risk of thrombosis relative to progestin-only contraception. We hereby identify an at-risk category of SLE patients with positive aPL on estrogen-based contraception, which is an area for improvement in our patient population. ACR recommends the use of an IUD or the progestin-only pill for SLE patients with positive aPL and does not currently recommend depo-medroxyprogesterone acetate IM shot or progestin implant. Our findings suggest that all forms of progestin-based contraception may be safe in SLE patients with positive aPL.

Supporting image 1

SLE patients with a positive aPL test had a statistically significant increased risk of thrombotic event such as cerebrovascular accident, pulmonary embolus, or deep venous thrombosis.

Supporting image 2

SLE patients with positive aPL test on estrogen-based contraception (oral combined estrogen-progestin pills) had a statistically significant increased risk of thrombotic event compared to those on progestin-based contraception (medroxyprogesterone acetate IM shot, progestin implant, progestin-only pill or levonorgestrel IUD). There was a total of 92 SLE patients with positive aPL testing receiving estrogen-based contraception.

Supporting image 3

SLE patients with positive aPL on various forms of progestin-based contraception (medroxyprogesterone acetate IM shot, progestin implant, progestin-only pill or levonorgestrel IUD) had no statistically significant difference in thrombotic events between groups.


Disclosures: H. Bilal, None; A. Baluch, None; A. Perl, None.

To cite this abstract in AMA style:

Bilal H, Baluch A, Perl A. Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positive SLE Patients on Estrogen-Containing Contraception [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/increased-prevalence-of-thrombotic-events-in-anti-phospholipid-antibody-positive-sle-patients-on-estrogen-containing-contraception/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-prevalence-of-thrombotic-events-in-anti-phospholipid-antibody-positive-sle-patients-on-estrogen-containing-contraception/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology